Kuros Biosciences AG

Kuros reports Corporate Highlights as of Q1 2024 including increase in direct MagnetOsTM sales

Annual General Meeting of Kuros Biosciences approves all resolutions

Kuros reports 163% growth in direct MagnetOs sales and 153% increase in total medical device sales for the full year 2023

Kuros Biosciences to Report Full Year Financial Results for 2023 and Provide Corporate Update

Kuros Biosciences to Present at the CG 2024 Musculoskeletal Conference

Kuros Biosciences Receives US FDA 510K Clearance for MagnetOs Granules for Interbody Use and Regulatory Clearance of MagnetOs Granules and MagnetOs Putty in New Zealand